AEGON ASSET MANAGEMENT UK Plc Reduces Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

AEGON ASSET MANAGEMENT UK Plc reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,071 shares of the company's stock after selling 1,795 shares during the quarter. AEGON ASSET MANAGEMENT UK Plc's holdings in IDEXX Laboratories were worth $13,458,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Hurley Capital LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at about $29,000. Rialto Wealth Management LLC purchased a new position in IDEXX Laboratories during the fourth quarter valued at approximately $30,000. Colonial Trust Co SC lifted its stake in shares of IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after purchasing an additional 39 shares during the period. Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter worth about $38,000. Finally, Itau Unibanco Holding S.A. grew its holdings in IDEXX Laboratories by 540.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after purchasing an additional 81 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Morgan Stanley upped their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Stifel Nicolaus boosted their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Finally, Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $536.00.

IDEXX Laboratories Trading Down 0.5%

NASDAQ:IDXX traded down $2.65 on Thursday, reaching $522.21. 453,158 shares of the company's stock were exchanged, compared to its average volume of 650,655. The firm has a market capitalization of $42.00 billion, a price-to-earnings ratio of 48.94, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $530.73. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The business has a fifty day moving average of $455.99 and a 200-day moving average of $439.27.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. During the same quarter last year, the company posted $2.71 EPS. The firm's revenue was up 3.6% compared to the same quarter last year. As a group, analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the sale, the director now directly owns 1,801 shares of the company's stock, valued at approximately $922,724.34. This represents a 41.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.